may 30, 2012 welcome to the fifth massachusetts life...

May 30, 2012

Welcome to the Fifth Massachusetts Life Sciences Innovation Day!

Once again, we bring together major organizations throughout the state to create a high-energy, hands-on event which includes scientific leaders and business experts to mingle with innovators, post-docs, professors, entrepreneurs, innovators, and venture capitalists. This is the biggest day for life sciences startups and innovation in the Commonwealth of Massachusetts.

This year’s theme is “The Burden of Proof.” As scientific breakthroughs progress from the moment of discovery through development to the market, inventors and developers have to show that the technol-ogy works - they have to “Prove It!” This conference will focus on how and when you have to prove your technology and what investors, regulators and payors need to understand about the product’s viability and efficacy. In this year’s panel sessions you will learn what data is required from the academic lab before the technology can be transferred to a company; what sort of “Proof of Concept” data is needed prior to pre-clinical work; what is required in the Clinic; and how new business models are being proved out following changes in the market.

Our keynote speakers and panelists have years of experience and represent a wide range of technolo-gies and inventions. They are presidents, CEOs, partners and consultants of leading companies and in-stitutions throughout the area. Some have attracted significant investments, while others have managed to achieve major milestones with very little funding. We hope you find their discussions informative and imaginative.

The Search for Proof Poster Competition returns with some of the greatest and newest ideas that could impact medicine in the future. Remember to invest your “MALSI dollars” in your favorite posters – it could help the inventors raise their first round of investment! Winners will be announced during our ever popu-lar evening reception attended by many CEOs who have taken on the judging of the posters. Don’t miss the opportunity to speak with them and discuss your projects.

We are particularly grateful to our Planning Committee for their help, support and entrepreneurial spirit in organizing this event. We would also like to thank all of our sponsors, particularly the Massachusetts Life Sciences Center and Pepper Hamilton LLP, who are our lead sponsors for this event. All of our sponsors are as committed as we are to support the creation of new companies and we are grateful to them all.

We hope you enjoy this, our flagship event of life sciences in Massachusetts, jointly and actively put to-gether by all the major organizations that are involved in starting and supporting the life sciences start-up ecosystem in the Commonwealth.

.

Dr. Abigail A. BarrowCo-Chair MALSIDirector, Massachusetts Technolgy Transfer Center

Lauren LaidlawCo-Chair MALSI Vice President, MassBio

5th AnnualMassachusetts Life Sciences Innovation Day

ii

Table of ContentsFloor Plan – Harvard Club of Boston .................................................................................. v

Conference Agenda ............................................................................................................. vi

Speaker Biographies .............................................................................................................. 9

Keynote ............................................................................................................................... 11Dr. Harvey F. Lodish ..................................................................................................................................11

Panel Moderators ................................................................................................................ 12Richard Anders ..........................................................................................................................................12Abigail Barrow ...........................................................................................................................................12Gene Barton ...............................................................................................................................................12Kevin Bitterman .........................................................................................................................................13Howard Golub ...........................................................................................................................................13Lauren Laidlaw ..........................................................................................................................................14Mark Namchuk ..........................................................................................................................................14Bruce Pratt .................................................................................................................................................14Susan Windham-Bannister ........................................................................................................................15

Panelists ............................................................................................................................... 16Omar Amirana ...........................................................................................................................................16Shelley Amster ...........................................................................................................................................16Daniel Behr ................................................................................................................................................16Richard Berenson .......................................................................................................................................17Gil Blander .................................................................................................................................................17George Demetri .........................................................................................................................................17Michael Elliott ...........................................................................................................................................18Greg Erman ................................................................................................................................................18Barbara Fox ................................................................................................................................................19Brian Gallagher ..........................................................................................................................................19Elisabeth George ........................................................................................................................................20Tillman Gerngross .....................................................................................................................................20Howard Golub ...........................................................................................................................................20Bill Gruber .................................................................................................................................................21Laurie Halloran ..........................................................................................................................................21William Kerns ............................................................................................................................................22Ankit Mahadevia ........................................................................................................................................22Bill Morton ................................................................................................................................................22Imran Nasrullah .........................................................................................................................................23Bernat Olle .................................................................................................................................................23John Reddington........................................................................................................................................24

May 30, 2012Harvard Club of Boston

iii

Kiran Reddy ...............................................................................................................................................24William Rodriguez ....................................................................................................................................24Yael Schwartz .............................................................................................................................................25Mark Sullivan .............................................................................................................................................25Ajay Verma .................................................................................................................................................25Waynne Waterfield ....................................................................................................................................26Pamela Weagraff .........................................................................................................................................26Bruce Wentworth .......................................................................................................................................27James Weston .............................................................................................................................................27Ray Winquist .............................................................................................................................................28

MALSI Day Planning Committee ..................................................................................... 29

Sponsors, Affiliates & Organizers ....................................................................................... 31Gold Sponsors ............................................................................................................................................32Conference Supporters ..............................................................................................................................34Organizers ..................................................................................................................................................35In association with .....................................................................................................................................39BIO 2012 ...................................................................................................................................................40

Poster Presenters ................................................................................................................. 41ARKOconsult ............................................................................................................................................43ASK Diagnostics ........................................................................................................................................43Boston College ...........................................................................................................................................43Boston University School of Medicine ......................................................................................................43Brown University .......................................................................................................................................43Brown University and Rhode Island Hospital...........................................................................................44Extend Biosciences, Inc .............................................................................................................................44GVD Corporation .....................................................................................................................................44Massachusetts Institute of Technology ......................................................................................................44Microtissues, Inc ........................................................................................................................................44Plate Technologies .....................................................................................................................................45Spordiff Therapeutics .................................................................................................................................45Synubi Pharmaceuticals .............................................................................................................................45Viridis Bio ..................................................................................................................................................45VitaThreads ................................................................................................................................................45Wellman Center for Photomedicine, MGH .............................................................................................46Worcester Polytechnic Institute.................................................................................................................46Wyss Institute at Harvard University ........................................................................................................46Wyss Institute at Harvard University ........................................................................................................46Wyss Institute at Harvard University ........................................................................................................46Wyss Institute at Harvard University ........................................................................................................47Wyss Institute at Harvard University ........................................................................................................47Wyss Institute at Harvard University ........................................................................................................47


iv

Innovator’s Marketplace Exhibitors .................................................................................... 49Life Science Products and Services ...........................................................................................................50Entrepreneurship Support .........................................................................................................................50Funding ......................................................................................................................................................51Professional Services ..................................................................................................................................51


v

Floor Plan – Harvard Club of Boston


vi

TIME SESSION

Foyer Harvard Hall

8:00 AM Registration & Breakfast

Harvard Hall

9:00 AM Welcome by Conference Co-chair Abigail Barrow, Director, Massachusetts Technology Transfer Center and Conference Co-chair Lauren Laidlaw, Director, Innovation Services & Events, MassBio

9:15 AM Opening Panel: CEOs Who Have Recently Raised MoneyPanelists:

Barbara Fox, CEO, Avaxia Richard Berenson, CEO, Thermalin Diabetes LLC

Gil Blander, President, Founder, and CSO, SeggterraBill Rodriguez, CEO, Daktari Diagnostics

Moderator: Gene Barton, Partner, Pepper Hamilton LLP

Harvard Foyer and Commonwealth Lounge on the 1st Floor

10:00AM NETWORKING BREAK / POSTER & STARTUP SHOWCASE

Massachusetts Room Aesculapian Room

10:30 AM Of Mice and Men; Finding the Early Results that Will Become Products

Panelists:George D. Demetri, Director, Center for Oncology, Dana-Farber Cancer Institute

Bernat Olle, Principal, PureTech VenturesAjay Verma, Vice President, Biogen Idec

Raymond Winquist, Vice President, Vertex

Moderator: Mark Namchuk, Senior Vice President of Research, Vertex

Getting Other People to Prove it for You

Panelists:Shelley Amster, Principal, ShelleyCO LLCKiran Reddy, Principal, Sage TherapeuticsYael Schwartz, CEO & President, Hygeia

Therapeutics Inc. Mark Sullivan, Founder and Director,

Medicines Development

Moderator: John Reddington, COO, Cambridge Biomedical Inc.

Harvard Hall - Lunch

12:00 PM Panel: The Data that Gets You the Deal with Big Pharma Panelists:

Mark Namchuk, Vice President of Research, VertexTillman Gerngross, Founder, Glycofi and Professor, Dartmouth College

Bruce Wentworth, Senior Director, GenzymeModerator: Richard Anders, Founder and Executive Director, MA Medical Angels

Harvard Hall

1:15 PM Keynote: “The Burden of Proof”Keynote Speaker: Dr. Harvey F. Lodish, Whitehead Institute for Biomedical Research,

Professor of Biology and Professor of Bioengineering, Massachusetts Institute of TechnologyIntroduction: Susan Windham-Bannister, President and CEO, MA Life Sciences Center


vii

TIME SESSION


2:00PM NETWORKING BREAK / POSTER & STARTUP SHOWCASE


2:30 PM Discussion: Clinical trials and proving your drugs work in humans

Panelists:Laurie Halloran, President & CEO, Halloran

Consulting GroupWilliam Kerns, Co-founder and CEO,

Accellient Partners LLCJames Weston, Senior Director CMC, Global Regulatory Affairs, Shire HGT

Moderator: Bruce Pratt, Principal Consultant, BioInnovation Consulting LLC

Discussion: Clinical trials and proving your devices work in humans

Panelists:Elisabeth George, Vice President of Global

Regulations & Standards, Philips HealthcareGreg Erman, President & CEO, EmpiraMedWilliam Morton, Senior Vice President, Aptiv

SolutionsPamela Weagraff, Principal Consultant,

Quintiles

Moderator: Howard Golub, Co-founder and Principal, Care-Safe LLC


3:30PM NETWORKING BREAK / POSTER & STARTUP SHOWCASE


4:00PM Discussion: What’s New on the Fund Raising Trail

Panelists:Daniel Behr, Senior Vice President, Access

BridgeGap VenturesMichael Elliott, VP and Entrepreneur in Residence, Janssen Pharmaceuticals,

Division of Johnson & JohnsonBrian Gallagher, Partner, SR One Ltd.

Ankit Mahadevia, Principal, Atlas Venture

Moderator: Kevin Bitterman, Partner, Polaris Venture Partners

Discussion: How Big Is Your Market and Does It Really Exist

Panelists:

Omar Amirana, Managing Director, Life Sciences, Allied Minds

Bill Gruber, President and CEO, SolaceImran Nasrullah, Head of Strategic Alliances,

T1D FirstWaynne Waterfield, Senior Practice

Executive, Campbell Alliance

Moderator: Abigail Barrow, Director, Massachusetts Technology Transfer Center

Harvard Hall

5:00 PM Reception / Innovators’ Marketplace / Poster and Invention Awards


8 Biographies


Biographies 9

Speaker BiographiesKeynote ............................................................................................................................... 11

Dr. Harvey F. Lodish ........................................................................................................... 11

Panel Moderators ................................................................................................................ 12

Richard Anders.................................................................................................................... 12Abigail Barrow .................................................................................................................... 12Gene Barton ........................................................................................................................ 12Kevin Bitterman .................................................................................................................. 13Howard Golub..................................................................................................................... 13Lauren Laidlaw .................................................................................................................... 14Mark Namchuk ................................................................................................................... 14Bruce Pratt ........................................................................................................................... 14Susan Windham-Bannister ................................................................................................. 15

Panelists ............................................................................................................................... 16

Omar Amirana .................................................................................................................... 16Shelley Amster ..................................................................................................................... 16Daniel Behr.......................................................................................................................... 16Richard Berenson ................................................................................................................ 17Gil Blander .......................................................................................................................... 17George Demetri ................................................................................................................... 17Michael Elliott ..................................................................................................................... 18Greg Erman ......................................................................................................................... 18Barbara Fox .......................................................................................................................... 19Brian Gallagher ................................................................................................................... 19Elisabeth George ................................................................................................................. 20Tillman Gerngross .............................................................................................................. 20Howard Golub..................................................................................................................... 20Bill Gruber .......................................................................................................................... 21Laurie Halloran ................................................................................................................... 21William Kerns ..................................................................................................................... 22Ankit Mahadevia ................................................................................................................. 22Bill Morton ......................................................................................................................... 22Imran Nasrullah .................................................................................................................. 23


10 Biographies

Bernat Olle .......................................................................................................................... 23John Reddington ................................................................................................................. 24Kiran Reddy ........................................................................................................................ 24William Rodriguez .............................................................................................................. 24Yael Schwartz ....................................................................................................................... 25Mark Sullivan ...................................................................................................................... 25Ajay Verma ........................................................................................................................... 25Waynne Waterfield ............................................................................................................. 26Pamela Weagraff .................................................................................................................. 26Bruce Wentworth ................................................................................................................ 27James Weston ....................................................................................................................... 27Ray Winquist....................................................................................................................... 28


Biographies 11

Speaker Biographies

Keynote

Dr. Harvey F. LodishMember, Whitehead Institute for Biomedical Research, Professor of Biology and Professor of Bioengineering, Massachusetts Institute of Technology

An illustrious leader in the field of molecular biology, Dr. Harvey F. Lodish has isolated and cloned numer-ous surface membrane proteins that play a role in blood development, cell signaling, glucose transport, and lipid metabolism. His results have made an impact on the treatment of anemia, cancer, diabetes and obesity. He earned his PhD with Dr. Norton Zinder at the Rockefeller University in 1966. A Founding Member of the Whitehead Institute, Dr. Lodish joined the MIT faculty in 1968 and has been a professor of biology since 1976 and professor of bioengineering since 1999. Dr. Lodish is also the lead author of the widely used text-book Molecular Cell Biology. The book has been translated into ten languages and the seventh edition will appear in 2012. He is a Member of the National Academy of Sciences, and served as Chair of the National Academy section on Cellular and Developmental Biology. He is also a Fellow of the American Association for the Advancement of Science, American Academy of Arts and Sciences, American Academy of Microbiology, and an Associate (Foreign) Member of the European Molecular Biology Organization. Dr. Lodish received a MERIT award from the National Institute of Diabetes and Digestive and Kidney Diseases. He is also a re-cipient of a Guggenheim Fellowship, an honorary D.Sc. from Kenyon, the Stadie Award from the American Diabetes Association, and the 2010 Mentoring Award from the American Society of Hematology. Dr. Lodish has served on advisory panels for the U.S. National Institutes of Health and National Science Foundation and the American Cancer Society. Dr. Lodish is a member of the Board of Trustees of Children’s Hospital, Boston, where he also is Chair of the Research Committee of the Board of Trustees. He is also Chair of the Scientific Advisory Board of the Massachusetts Life Sciences Center, the group charged with oversight of the state’s 10- year $1 billion investment in the life sciences. Dr. Lodish was a founder and scientific advisory board member of Genzyme, Arris, Millennium and Allozyne. He has served on the Scientific Advisory Board for the Eisai Research Institute and AstraZeneca Pharmaceuticals. He has also testified as an expert witness in several high-profile patent trials in Federal Court, notably Amgen vs. TKT Aventis in 2000 and Amgen vs. Roche in 2007.


12 Biographies

Panel Moderators

Richard AndersFounder and Executive Director, MA Medical Angels (MA2)

Richard Anders, is a lawyer turned entrepreneur. In 1984 he founded Jurisoft, which he later sold to Lexis/Nexis. He later was the publisher of Boston Digital Industry and New York Digital Industry, and currently is Managing Director of Rubin/Anders Scientific. Richard is a trustee of the Boston Museum of Science, a member of the MIT/Harvard Medical School HST program advisory council where he helps teach a course on the biomedical enterprise, and a trustee of the Boston Biomedical Research Institute. He is a member of the Institutional Review Board at the Dana Farber Cancer Center. He founded the angel groups Launchpad and in 2008, MA Medical Angels (MA2), one of the country’s only angel groups focused exclusively on life sciences. Richard is a graduate Summa Cum Laude in mathematics from Harvard and holds a J.D. from Harvard Law School.

Abigail BarrowFounding Director, Massachusetts Technology Transfer Center and Conference Co-Chair

Dr. Abigail Barrow is the Founding Director of the Massachusetts Technology Transfer Center (MTTC). The MTTC is state funded and supports technology transfer activities from public and private research institutions to companies in Massachusetts. The Center works with technology transfer offices at all research institu-tions; faculty, researchers, and students who have commercially promising ideas; and companies across the Commonwealth. Prior to joining the MTTC, Dr. Barrow served as managing director of William J. von Liebig Center at the University of California San Diego (UCSD). The von Liebig Center was created in 2001 to support the commercialization of research being performed in the Jacobs School of Engineering. Dr. Bar-row worked in a variety of roles at UCSD CONNECT from 1990 to 2001. CONNECT’s programs focused on supporting early stage high-tech and biotech companies and in particular helping them raise funding from venture capitalists and corporate partners. Dr. Barrow has also worked with other regions where the CON-NECT program has been successfully replicated, including Scotland and Scandinavia. Dr. Barrow is a Fellow of UCSD’s Beyster Institute and an Xconomist for Xconomy.com.

Gene BartonPartner, Pepper Hamilton LLP

Gene T. Barton, Jr. is a partner in the Corporate and Securities Practice Group of Pepper Hamilton LLP in the Boston office. Mr. Barton’s practice emphasizes merger and acquisitions activity. He specializes in the rep-resentation of high growth companies and venture capital and other private equity funds. He also provides general corporate, business planning and strategic advice to corporations and their senior corporate execu-tives. Mr. Barton’s representative transactions include: sale of Calnetix Power Solutions to GE Healthcare; sale of Direct Drive Systems to FMC Corp.; acquisition of Merck’s Natural Products Division by NPJV LLC; sale of Venture Tape Corporation to 3M representing management of HCPro in leverage recapitalization led by Halyard Capital; sale of Published Image, Inc. to Standard and Poors, Inc.; sale of Cross Industry Com-munications to Protocol Holdings; sale by A.W. Chesterton Company of two of its divisions; sale of the Con-


Biographies 13

solidated Group, Inc. to Health Plan Systems, Inc.; sale of Qiave Technologies Corporation to WatchGuard Technologies Corporation; sale of The Credit Network to Kroll; acquisition of BOMA, srl by Venture Tape; sale of Beacon Fiduciary Advisors to the Bank of New York Company, Inc.; and venture capital financing of E5 Systems by Bain Capital. Gene T. Barton holds B.A. 1979, cum laude, from Boston University and J.D., magna cum laude, from Boston University School of Law.

Kevin BittermanPrincipal, Polaris Venture Partners

Kevin J. Bitterman is a Principal at Polaris Venture Partners. He joined Polaris in 2004 and focuses on invest-ments in the life sciences. Prior to joining Polaris, Kevin completed his Ph.D. in genetics at Harvard Medical School. He is a cofounder of Genocea Biosciences and Sirtris Pharmaceuticals (GSK) and was the found-ing CEO at Visterra Inc. Kevin has played an active role in over two dozen new investments since joining Polaris and he currently represents the firm as a Director of Direct Vet Marketing, Follica, Genocea Biosci-ences, InSeal Medical, Kala Pharmaceuticals, Neuronetics, Taris Biomedical and Visterra. Additionally, Kevin is a Board Observer to Pulmatrix. is a Principal at Polaris Venture Partners. He joined Polaris in 2004 and focuses on investments in the life sciences. Prior to joining Polaris, Kevin completed his Ph.D. in genetics at Harvard Medical School. He is a cofounder of Genocea Biosciences and Sirtris Pharmaceuticals (GSK) and was the founding CEO at Visterra Inc. Kevin has played an active role in over two dozen new invest-ments since joining Polaris and he currently represents the firm as a Director of Direct Vet Marketing, Follica, Genocea Biosciences, InSeal Medical, Kala Pharmaceuticals, Neuronetics, Taris Biomedical and Visterra. Additionally, Kevin is a Board Observer to Pulmatrix.

Howard GolubCo-founder and Principal, Care-Safe LLC

Over the first 30 years, Dr. Golub was founder and CEO of a number of medical device companies. They include PDS Inc., a medical computer based diagnostic device company, which was sold to Tokos Medical Corp. in 1990, Venturcom Inc. (a computer software company) and had served on its board of directors which was acquired in 1998, Cry Research Inc. a company formed to determine the clinical usefulness of infant cry analysis (a technology he developed as part of his Ph.D. work), and the patent holder of the central IP and CEO of DxTek Inc. a medical device company (that developed a continuous, cuffless non-invasive blood pressure device). In 1995, Dr. Golub was founder and CEO of MSO-NY, a Management Service Organization setup as a partnership of physicians and managed care experts to provide all necessary managed care the New York City area. Also in 1995, Dr. Golub was founder, president and one of the medical monitors of Car-eStat Inc. CareStat, based in Boston, was a full service Clinical Research Organization (CRO) specializing in FDA based registration trials for pharmaceuticals, biotech and medical devices. CareStat was acquired by Battelle Memorial Institute in 2005, where he served as the president of their clinical trials subsidiary until 2008. In 2009, Dr. Golub was one of the founders and Principals of Care-Safe LLC, a small, senior clinical development consulting company. Dr. Golub currently holds an appointment as Senior Lecturer in the M.I.T.-Harvard Joint Program where he teaches the Clinical Trials Course (a program that he is an alum) and as a Distinguished Fellow at the Center for Biomedical Innovation also at M.I.T. In addition, he has an adjunct appointment at the Boston University School of Public Health in Biostatistics and Epidemiology.


14 Biographies

Lauren LaidlawVice President, Innovation & Member Services, MassBio

Lauren joined MassBio in September of 2008 as the Director of Member Services. She oversees all aspects of membership and business development for the council. Lauren also manages all of the MassBio Signature Events, from programming elements to sponsorship opportunities. Prior to joining MassBio, Lauren worked at Cambridge Energy Research Associates where she held various positions in event management, mem-bership services and marketing.

Lauren holds a B.A. from Suffolk University. She resides in Everett, Mass., with her husband, Matt, and two children, Iggy and Ollie.

Mark NamchukSenior Vice President of Research for North America, Vertex Pharmaceuticals

Dr. Namchuk received his BSc in Chemistry with Honors from the University of Alberta in 1988 and his Ph.D. in Bioorganic Chemistry from the University of British Columbia in 1993. Upon completion of his graduate work, Dr. Namchuk was an HFSP Post Doctoral Fellow at UCSF. In 1996 he accepted a position with Cub-ist Pharmaceuticals as the head of the Enzymology group. In 1998, he joined Vertex Pharmaceuticals and has held a number of positions with the company. In 1999, he took on responsibility for the High Throughput Screening group. After leading drug discovery teams in infectious disease and oncology, he was promoted in 2002 to Worldwide Head of preclinical research for the Vertex/Novartis Kinase Program, and in 2003 took responsibility for all aspects of the alliance across R and D. In 2005, Dr. Namchuk was made Vice President of Research for Vertex’s Cambridge site. In 2011 he was promoted to his current position as senior Vice President of Research for North America. In this position he manages 350 scientists in 4 sites working in all areas of pharmaceutical research including Medicinal Chemistry, Structural Biology, Biochemistry, Cell Biol-ogy and Pharmacology and oversees projects in areas of Infectious Disease, Oncology, IMID, Neurology and Cystic Fibrosis.

Bruce PrattPrincipal Consultant, BioInnovation Consulting LLC

Dr. Bruce Pratt is Principal Consultant at BioInnovation Consulting LLC, where he works with early stage bio-technology companies on science and technology aspects of strategic and tactical issues, for example, lead indication selection, preclinical experimental design, market identification and focus, and preparation for fi-nancing or strategic partnering events. Dr. Pratt was previously VP, Science Development for Genzyme Cor-poration, with responsibilities in the identification and evaluation of early stage therapeutic opportunities and proactive, selective outreach activities to the academic, biotechnology, and life science sectors. He worked for Genzyme for 22 years, initially in positions of increasing responsibility in Cell & Protein Therapeutics Re-search & Development, culminating as Sr. Director of Cell Biology. From 2002 through 2004, he was based in one of Genzyme’s European offices, identifying early stage European research and product opportunities. Following his return to the United States in 2004, he continued his role in early stage opportunity identifica-tion and outreach to the biotechnology and academic sectors. Prior to Genzyme, Dr. Pratt worked at Col-lagen Corporation and Celtrix Pharmaceuticals in Palo Alto, California. He earned his Ph.D. from Michigan State University and was a post-doctoral fellow and Associate Research Scientist at Yale University School of Medicine, Department of Pathology.


Biographies 15

Susan Windham-BannisterPresident and CEO, Massachusetts Life Sciences Center

On May 28, 2008, Dr. Susan Windham-Bannister was appointed by the Massachusetts Life Sciences Center Board of Directors to be the Center’s first President and CEO. She officially assumed that position in July, 2008.

The Massachusetts Life Sciences Center is a quasi-public entity created by the Legislature in 2006 to pro-mote the life sciences within Massachusetts. The Center is at the heart of the state’s new $1 billion life sci-ences law and is fast becoming the hub of connectivity for all sectors of the life sciences community - encour-aging unprecedented public-private collaboration among industry, research, academia and government. The Center is making strategic investments in our life sciences workforce and in translational research at critical stages of the development cycle. These investments will foster and grow the Massachusetts life sciences Super Cluster, cultivating innovation at institutions whose research, development and commercialization of therapies, products and cures hold great promise for improving and saving lives.

Dr. Windham-Bannister is former Managing Vice President of the Commercial Strategy Group for Abt Bio-Pharma Solutions Inc. In that capacity, she managed a research-based consulting business that provides consulting services to firms in the life sciences -- health care delivery, pharmaceuticals, biotech, diagnostics, devices and healthcare information technology.

Dr. Windham-Bannister was a member of Abt Bio-Pharma Solutions’ corporate management team, and a founding member of the commercial division of Abt Associates, the parent company.

Dr. Windham-Bannister has 35 years of consulting experience in life sciences and has worked with com-panies that represent all major industry sectors. A partial list of her clients includes Siemens Diagnostics, Roche, Pfizer, Genzyme, Eyetech, Sopherion, Sanofi, Novartis, Massachusetts General Hospital, Brigham and Women’s Hospital, Tufts Medical Center, GE Healthcare, The American Cancer Society and The W.K. Kellogg Foundation. Within her client organizations, Dr. Windham-Bannister most often works with executive level management and/or Boards of Directors on assessment of market opportunities and commercialization strategy.

Dr. Windham-Bannister has co-authored two books: Competitive Strategy for Health Care Organizations and Medicaid and Other Experiments in State Health Policy. She also has written several articles on competition in today’s health care marketplace.

She sits on a variety of Boards of Directors and is a frequent speaker and panelist at conferences on com-petitive strategy.

Dr. Windham-Bannister holds a B.A. from Wellesley College, a doctorate in health policy and management from the Heller School at Brandeis University, and was a post-doctoral fellow at Harvard University’s John F. Kennedy School. She completed her doctoral work under a fellowship from the Ford Foundation.


16 Biographies

Panelists

Omar AmiranaManaging Director, Life Sciences, Allied Minds

Omar is the Managing Director, Life Sciences at Allied Minds. Prior to joining Allied Minds, he served as a Partner at Oxford Bioscience Partners, a Boston-based life sciences venture capital firm with ~$1B under management. He is currently on the board of Cardiofocus (catheter ablation of AF) and Cambridge Endo-scopic Devices (articulating laparoscopic surgical tools), and served on the boards of Coherex (catheter closure of LAA and PFO), Smartpill (GI diagnostic capsule technology), Mitralign (percutaneous heart valve repair), NFocus (catheter based aneurysm therapy), and Flowmedica (targeted renal therapy). He was the co-founder of two medical device companies, Cardima and Resolution Medical, and was the VP of Market-ing of MedicaLogic/Medscape, a leading EMR/HCIT company. He also served as VP of Business Develop-ment at St Jude Medical (STJ, $5.2B in revenue) focused on cardiology and vascular intervention. He has launched products worldwide. As the co-founder of Propel Careers, he is passionate about helping aspiring entrepreneurs in life sciences. Omar earned a BS in Mechanical Engineering from Tufts University and an MD from Eastern Virginia Medical School.

Shelley AmsterFounder and Principal, ShelleyCO, LLC

Shelley Amster, Founder and Principal, ShelleyCO, LLC, and Executive Director and Founder, The NEWISE Club, is the life science connector and relationship catalyst. She judiciously nurtures healthy business and scientific relationships, uncovers new opportunities, and provides business development resources for her clients. For the 20 previous years, Shelley was a pioneer in the infertility/IVF industry initially as one of the first clinical lab directors in the US and then as an entrepreneur facilitating the commercialization of products and services in that industry. In all situations, Shelley is known for bringing the right people and resources together in a timely matter.

Daniel BehrSenior Vice President, Access BridgeGap Ventures

Daniel Behr is an experienced entrepreneur, venture investor and technology development professional. In the past 25 years he has created and funded numerous ventures in the life and physical sciences. Daniel is currently Senior Vice President and a founder of Access BridgeGap Ventures, the early-stage life sciences venture investment unit of Access Industries, Inc. He was Director of Technology Ventures at Allied Minds, Inc., an investment firm focused on academic spinoffs. Daniel was Director of Business Development at Har-vard University’s Office of Technology Development (technology transfer) where he helped launch 7 spinoffs. Prior to that, Daniel co-founded and held executive positions in 3 companies (In USA, Compact Instruments, Arradiance), and he co-founded a seed-stage angel investment fund (Seed Partners, LP). He was a Strat-egy Consultant at Bain & Co. and an advanced materials Research Engineer at Albany International. Daniel earned an MBA with distinction from the Harvard Business School and a BS in Engineering with highest honors from the Georgia Institute of Technology. He speaks German and is fluent in Spanish.


Biographies 17

Richard BerensonChief Executive Officer, Thermalin Diabetes LLC

Richard Berenson is Chief Executive Officer of Thermalin Diabetes, LLC, where to date he has raised $11.5M in dilutive and non-dilutive capital. Rick has been leading and building early-stage organizations for twenty-five years; he has been CEO or COO of eleven companies and the CFO/Treasurer of several more; in these roles he has raised or helped raise more than $27M in private capital. As Managing Director of his consulting firm, Venzyme Catalyst, LLC, he has successfully helped launch and finance many life science organizations around important new technologies in complex markets.

Rick began his career at AT&T Bell Laboratories where he helped launch internal ventures. He then spent several years at software startups in the Boston area before joining McKinsey & Company as a management consultant. Since then, Rick has been CEO of HeartLander Surgical (medical devices), ActivBiotics (early stage biotech), Banton Precision Wood Products (consumer products), NewSphere (knowledge manage-ment), Student.Com, Inc. (new media), TVGrid (entertainment industry technology), and Foresight Systems (manufacturing software). He has also served in C-level roles at ChannelHealth.Com (healthcare information and services), Morpace Pharma Group (market research), PersonaDX (reference laboratory), InCytu (can-cer immunotherapetuics), and SimulConsult (differential diagnosis software). Rick received a JD-MBA from Harvard Law and Business Schools in 1984 and is a graduate of Harvard College.

Gil BlanderFounder, President, and Chief Scientific Officer, Segterra

Dr. Blander received his BSc in Biology with Honors from Tel-Aviv University of in 1995 and his Ph.D. in Biology from the Weizmann Institute of Science in 2002. Upon completion of his graduate work, Dr. Blander was an EMBO and Estee Lauder Post Doctoral Fellow at MIT. In 2007 he accepted a position with Genstruct Inc. as R&D team lead. In 2009, he joined Intelligent Bio-Systems and has held a number of positions with the company. In 2009, he founded Segterra Inc. Segterra scientific advisors includes physicians, scientists, exercise physiologists, and nutritionists from MIT, Harvard, and Tufts University. Segterra created the Inside-Tracker service to provides a web-based, personalized path to health, wellness and performance.

George DemetriDirector, Center for Oncology, Dana-Farber Cancer Institute

Dr. George Demetri received an undergraduate degree in Biochemistry from Harvard University, followed by a Research Fellowship at the Université de Besancon, France, after which he received his medical degree from Stanford University School of Medicine, California, USA. After completing Internal Medicine residency and chief residency at the University of Washington Hospitals in Seattle, Washington, he completed the fel-lowship in Medical Oncology at the Dana-Farber Cancer Institute (DFCI) and Harvard Medical School, where he has served as an attending physician since 1989. Dr Demetri and the multidisciplinary team at Dana-Farber/Harvard Cancer Center have developed one of the largest centres of excellence for research and care of sarcoma patients, focusing on the development of novel therapies, enabled by directing the Ludwig Center at Dana-Farber Harvard and the Center for Novel Experimental Therapeutics at Dana-Farber.


18 Biographies

Dr Demetri’s research and clinical interests have centered on mechanism-based drug development for solid tumours, with a particular emphasis on molecularly-defined subsets of sarcomas such as gastrointestinal stromal tumours (GIST). Dr. Demetri and colleagues at Dana–Farber/Harvard have contributed to the devel-opment of several new drugs for sarcomas and other malignancies, including imatinib, sunitinib, dasatinib, trabectedin, vemurafenib, everolimus, pazopanib, regorafenib and other new targeted therapies in develop-ment. Dr Demetri serves as chair of the Medical Advisory Board for the Sarcoma Foundation of America as well as several scientific and editorial advisory boards. With an interest in internet-based patient support, he also serves on the Medical Advisory Board of ASCO’s CancerNet (www.cancer.net) as well as CancerCom-mons.org.

Michael ElliottVice President and Entrepreneur in Residence, Janssen Pharmaceuticals, a Division of Johnson & Johnson

Dr. Elliott is a physician-scientist and drug developer. He has spent much of his career in the biotech and pharmaceutical industry, working in large and small companies. His J&J career includes 7 years at Cento-cor, where he led the clinical development of Centocor’s monoclonal antibody (mAb) products in immune and inflammatory disorders. Foremost amongst these were the development and regulatory approval of the anti-TNF mAb infliximab (REMICADE) in rheumatoid arthritis, Crohn’s disease, ulcerative colitis and other inflammatory indications, and of the follow-on anti-TNF mAb, golimumab (Simponi) in a range of rheumatic diseases. His group also led clinical development of the first in class anti-IL-12/23 mAb, ustekinumab (Ste-lara) for the treatment of psoriasis. More recently, Dr Elliott served as General Manager and Site Head at TransForm Pharmaceuticals, a J&J company focused on high throughput drug formulation, and served as a member of the J&J Corporate Office of Science and Technology. In January 2012, Dr Elliott transitioned to the role of Janssen Entrepreneur in Residence at Polaris Ventures, where he is working to build a portfolio of early stage pharma and biotech companies of interest to both Janssen and Polaris. Dr Elliott earned his medical degree (MBBS) and PhD from the University of Adelaide, Australia, and is a Fellow of the Royal Aus-tralasian College of Physicians. His early scientific work at the University of Adelaide and at the Walter and Eliza Hall Institute in Melbourne included studies on the biology and receptor interactions of the hemopoietic growth factors, GM-CSF and IL-3. At the Kennedy Institute of Rheumatology in London, he worked on the first clinical trials of anti-TNF therapy in rheumatoid arthritis, and was lead author on several acclaimed publi-cations that provided clinical validation for this radical new approach to therapy. Dr Elliott has authored many peer-reviewed journal articles, reviews and book chapters in the field of cytokine immunology and protein therapeutics.

Greg ErmanPresident & CEO, EmpiraMed

Greg Erman is President & CEO of EmpiraMed, a health outcomes technology company. Greg’s career cen-ters on entrepreneurship, technology commercialization, and business leadership. He incubated roughly 250 academic medical research projects over the last 10 years, raised about $100M in venture capital, and suc-cessfully grew businesses to about $20M in annual revenue. Each of Greg’s 3 VC-backed companies suc-cessfully exited to large public corporations and generated returns up to 12X investment. Operationally, Greg has been President & CEO of 6 companies including Illumasonix, an ultrasound system for vascular surgery; Precision Biopsy, an optical guided prostate cancer biopsy device; Renalworks Medical Corporation, a VC-


Biographies 19

backed MGH/MIT spin-out which built an implantable hemofilter for ESRD & CHF; MarketSoft Corporation, a VC-backed enterprise software company in the marketing & sales automation field; and Waypoint Software Corporation, a VC-backed industrial B2B eCommerce internet firm. Greg holds BSEE and Marketing MBA degrees with high honors from Rutgers University, is a mentor in six different organizations, and sits on nu-merous boards of directors and advisory boards including the Harvard University Wyss Institute Accelerator Fund Investment Committee. Greg’s avocations include coastal sailing & racing, tennis, jazz trumpet, and skiing.

Barbara FoxFounder and CEO, Avaxia Biologics

Barbara S. Fox, PhD, is founder and CEO of Avaxia Biologics, a company developing orally delivered an-tibody therapeutics designed to act locally in the gastrointestinal tract. Avaxia’s lead product is an orally delivered anti-TNF antibody being developed for both inflammatory bowel disease (Crohn’s disease and ulcerative colitis) and gastrointestinal acute radiation syndrome. Avaxia is funded by $4M from angel inves-tors and $5.8M in non-dilutive funding. Dr. Fox’s previous positions have included Affiliated Entrepreneur at Oxford Bioscience Partners; founder, President and Chief Scientific Officer of Recovery Pharmaceuticals; Vice President, Immunology at ImmuLogic Pharmaceutical Corp.; and Associate Professor of Rheumatology and Clinical Immunology at the U. Maryland School of Medicine. Dr. Fox received her PhD in Chemistry from MIT and trained as a post-doc in cellular immunology at the NIH.

Brian GallagherPartner, SR One Ltd.

Brian established the SR One Boston office in 2010 and is focused on building innovative therapeutic and device life science companies. He currently represents SR One on the boards of Aileron Therapeutics, Con-stellation Pharmaceuticals, Dicerna Pharmaceuticals, RaNA Therapeutics, and SpringLeaf Therapeutics. He has nearly 15 years of investing, business development, operational, and R&D experience in both biotech-nology and large pharma companies. He joined SR One from Sirtris Pharmaceuticals where he was respon-sible for corporate development, operations, and post-merger integration following the $720 million acquisi-tion of Sirtris by GlaxoSmithKline in 2008. Prior to Sirtris, Brian was with Alantos Pharmaceuticals where he played key roles in the R&D and business development activities, and led many aspects of the post-merger integration following the $300 million acquisition of Alantos by Amgen in 2007. Brian began his career in R&D at the Japanese pharma Eisai where he was a group leader for multiple programs in the oncology and inflam-mation/immunology therapeutic areas. He is an inventor on over twenty-five patents and patent applications, and is the senior author of a number of scientific publications. He currently serves on the editorial board of the journal Marine Drugs and is a peer reviewer for numerous journals and research funding authorities. Brian received his M.S. and Ph.D. degrees in Organic Chemistry from The University of Michigan, and a B.S. in Chemistry from The University of Massachusetts where he was awarded a full scholarship.


20 Biographies

Elisabeth GeorgeVice President of Global Government Affairs, Regulations and Standards, Philips Healthcare

Elisabeth supports management of strategic planning and technical aspects for global regulations and stan-dards including areas in quality, reliability, safety, product security, privacy and sustainability compliance for Philips Healthcare business around the world. She is responsible for technical teams ensuring worldwide compliance and continual improvement in product submissions, post-market surveillance, product reliability improvement, International standards and regulations, quality systems (ISO13485, 21CFR), and environ-mental management system (ISO14001 & OHSAS 18001) for the following product families: Home Health-care, Patient Monitoring Systems, Healthcare Informatics, Defibrillators, Cardiographs, X-Ray Systems, MR Systems, CT Systems, Nuclear Medicine Solutions and Generators, Tubes, and associated Components with design, manufacturing and distribution around the world. Speaker, Panel member and Advisory Boards at many events and conferences including AdvaMed, AAMI, Frost & Sullivan, Brazil, India, Korea and China Regulatory Forums for local & global industry, AHWP members and/or regulators with topics including QMS, CAPA, Submissions, IEC60601 Standards Radiation Safety and GHTF documents. Medical Devices 2012 Frost & Sullivan Executive MindXchange Advisory Board. Committee co-chairperson and participant roles for AdvaMed 2012. Elisabeth holds Bachelor of Science in Biomedical Electrical from Boston University College of Engineering and Masters of Science in Engineering Management from Northeastern University

Tillman GerngrossFounder, Glycofi and Professor, Dartmouth College

Tillman Gerngross, Ph.D., is a Professor of Bioengineering at Dartmouth College and active innovator and entrepreneur who has founded several successful venture backed companies. At GlycoFi, his first venture, Prof. Gerngross developed a novel method for humanizing the glycosylation machinery in yeast to produce therapeutic proteins, including antibodies, with fully human carbohydrate structures. In 2006 Merck acquired the company for a record-setting $400 million. The same year Nature Biotechnology named Gerngross one of the most notable people in Biotechnology in the past ten years. In the fall of 2006 Gerngross joined SV Life Science (formerly Schroder Ventures Life Science) as a Venture Partner to advise on investment oppor-tunities in the bio-therapeutics area. In 2007 Gerngross co-founded Adimab, which over the past four years has developed a premier antibody discovery technology and in the last two years has signed partnerships with many of the world’s leading pharmaceutical companies. In 2010 Adimab was awarded the Technology Pioneer award by the World Economic Forum in Davos. In 2010 Gerngross founded Arsanis Inc. to develop antibody based strategies for the treatment of infectious diseases.

Howard GolubCo-founder and Principal, Care-Safe LLC

Over the first 30 years, Dr. Golub was founder and CEO of a number of medical device companies. They include PDS Inc., a medical computer based diagnostic device company, which was sold to Tokos Medical Corp. in 1990, Venturcom Inc. (a computer software company) and had served on its board of directors which was acquired in 1998, Cry Research Inc. a company formed to determine the clinical usefulness of infant cry analysis (a technology he developed as part of his Ph.D. work), and the patent holder of the central IP and CEO of DxTek Inc. a medical device company (that developed a continuous, cuffless non-invasive blood


Biographies 21

pressure device). In 1995, Dr. Golub was founder and CEO of MSO-NY, a Management Service Organization setup as a partnership of physicians and managed care experts to provide all necessary managed care the New York City area. Also in 1995, Dr. Golub was founder, president and one of the medical monitors of Car-eStat Inc. CareStat, based in Boston, was a full service Clinical Research Organization (CRO) specializing in FDA based registration trials for pharmaceuticals, biotech and medical devices. CareStat was acquired by Battelle Memorial Institute in 2005, where he served as the president of their clinical trials subsidiary until 2008. In 2009, Dr. Golub was one of the founders and Principals of Care-Safe LLC, a small, senior clinical development consulting company. Dr. Golub currently holds an appointment as Senior Lecturer in the M.I.T.-Harvard Joint Program where he teaches the Clinical Trials Course (a program that he is an alum) and as a Distinguished Fellow at the Center for Biomedical Innovation also at M.I.T. In addition, he has an adjunct appointment at the Boston University School of Public Health in Biostatistics and Epidemiology.

Bill GruberPresident and CEO, Solace Therapeutics

Bill Gruber is currently the President and CEO of Solace Therapeutics, a startup company in the female uri-nary incontinence field. Bill was the President and CEO of Interlace Medical. While at Interlace he raised over $28MM in venture capital for the development and launch of devices for the treatment of Abnormal Uterine Bleeding caused by fibroids. The company was purchased by Hologic in 2011 for $125MM plus contingent payments. Bill has extensive experience in organizational development and in product development for rapid growth businesses. Before joining Interlace Medical, he was President of Hemedex, Inc. where he led fund-raising efforts and developed the company’s business plan. Prior to joining Hemedex, Bill spent five years at Cortek Inc., a spinal products company. As Cortek’s V.P. of Sales and Marketing, he built sales from $612K to over $10M. During his last two years, he was the V.P. of New Business Development and Marketing where he was instrumental in creating Soteira, a Cortek subsidiary, which focused on devices for treating vertebral compression fractures. Earlier in his career, Bill spent ten years at Boston Scientific Corporation, concluding his career at BSC as Director of the $172M Global Atherosclerotic Therapy business. Bill began his career in sales and marketing roles at Procter and Gamble before transitioning into the medical device sector.

Laurie HalloranPresident & Chief Executive Officer, Halloran Consulting Group

Laurie founded Halloran Consulting Group in 1998. With over 25 years of experience in clinical affairs man-agement with contract research organizations and biotechnology companies, Laurie is recognized as an industry expert in improving the organizational effectiveness of clinical research programs with a specialty in gap analysis and strategic planning. Laurie has managed 25+ clinical trials from Phase I to Phase III for both emerging and established companies and has managed operational budgets of up to $24 MM. Prior to founding Halloran Consulting Group, Laurie spent 10 years at PAREXEL International where she developed worldwide training capabilities with the clinical operations group. She has also established clinical operations at OXiGENE and Antigenics. She is an adjunct professor at Boston University Medical School, has taught at George Washington University, and Harvard, and lectures at the Tufts Center for Drug Development Post-Graduate program. In 2010, she was selected as one of the 100 Most Inspiring People in Life Science by PharmaVoice and in 2009 was awarded Clinical Researcher of the Year by the New England Chapter of the Associate of Clinical Research Professionals. Laurie earned a B.S. in Nursing from Russell Sage College and an M.S. in Management from Leslie University. She is also a Prosci certified change management con-sultant.


22 Biographies

William KernsCo-founder CEO of Accellient Partners, LLC

Dr. Kerns is an entrepreneur and co-founder CEO of Accellient Partners, LLC, a drug development consul-tancy. He completed his medical training in Veterinary Medicine and graduate work in Pharmacology and Pathology at The Ohio State University. In his graduate program, he studied molecular mechanisms of car-diac hypertrophy. In 1980, he successfully completed examination by the American College of Veterinary Pathologists. Dr. Kerns has 30 years of experience in pharmaceutical research and development, having held senior executive positions in preclinical development at SmithKlineFrench, SmithKlineBeecham (both now part of GlaxoSmithKline), and Eisai during his pharmaceutical career. He is recognized as an expert in drug development and safety assessment with a focus on mechanisms of drug-induced cardiovascular toxicity. He has authored or co-authored over 100 articles and has co-edited a book on cardiovascular toxicology. He has been actively involved in the SOT, STP and ACVP and he has co-chaired an FDA ex-pert committee on biomarkers of drug-induced vascular injury. Dr. Kerns has participated in the successful management and activation of over 200 INDs and 15 NDAs during his career. Currently he oversees the submission of 3-4 INDs each year across multiple divisions at FDA. Dr. Kerns is also a co-founder and the interim CEO of Synchroneuron Inc, a VC-backed development stage biotechnology company working on the treatment for tardive dyskinesia and other movement disorders.

Ankit MahadeviaPrincipal, Atlas Venture

Ankit Mahadevia joined Atlas Venture in 2008 as an Associate and became a Principal in 2010. Previ-ously, Ankit worked on product and business development with the founding team at Arcion Therapeutics, a specialty pharmaceutical company developing topical applications in neuropathic pain. Before Arcion Therapeutics, he held positions in Business Development at Genentech, and at Vanda Pharmaceuticals, a specialty pharmaceutical company focused on targeted therapies in psychiatry. He also served clients in the health services sector at McKinsey and Company and was a Consultant at Monitor Group, where he supported clients in the biotechnology and medical device industries on strategy, marketing, and busi-ness development. Ankit also held roles in health policy at the Senate Health, Education, Labor, and Pen-sions Committee, the U.S. Government Accountability Office, and the Mexican Institute of Social Security (IMSS).

Ankit completed his MD at Johns Hopkins University School of Medicine, and his MBA at the Wharton School at the University of Pennsylvania. He graduated summa cum laude with a Bachelor of Arts in Eco-nomics and Biology from Northwestern University. During his medical training Ankit published research in glaucoma therapy and neurovascular interventions. Ankit serves on the board of Lumavita AG and Fibrex Medical and works closely with the Atlas Venture Development Corporation and the Atlas/Monsanto See Fund Alliance. He also serves on the board of the Johns Hopkins Technology Alliance and as a reviewer for the National Cancer Institute SBIR Bridge Awards.

Bill Morton Senior Vice President, Aptiv Solutions

Bill has over thirty years of experience in the field of business management, medical device research, development, and regulatory compliance. In 1980, Bill founded Medical Device Consultants, Inc. (MDCI),


Biographies 23

a consulting firm and CRO providing regulatory consulting and clinical trial management, monitoring and data management services to medical device and IVD product manufacturers. He grew MDCI to a 60 per-son organization until it was acquired by Aptiv Solutions in 2011. Prior to founding MDCI, Bill was Director of Regulatory Affairs and Clinical Studies for AVCO Medical Products Division of AVCO Corporation. Bill has contributed numerous publications to scientific literature and is a Fellow of the Regulatory Affairs Profession-als Society (RAPS) and is Regulatory Affairs Certified. He serves on the editorial advisory boards for Medi-cal Product Outsourcing and Medical Device Technology. He served as chairman of the Regulatory Affairs Certification Board for RAPS from 2003 to 2006 and the Board of Directors of RAPS from 2007 - 2009. He holds a B.S. in materials science from San Jose State University.

Imran NasrullahHead of Strategic Alliances, T1D First

Imran Nasrullah has close to 20 years experience in biotechnology. Imran has spent over 16 years in busi-ness in both corporate and academic spheres. Imran heads strategic alliances for T1D First, a disease foundation dedicated to curing Type 1 Diabetes. As Head of Strategic Alliances, Imran will forge partnerships with industry, academic and not-for-profit partners. T1D First currently consists of a biobank, clinical registry, and Glu, an online social network for people with type 1 diabetes. The T1D Exchange was founded in 2010 through a grant from Leona M. and Harry B. Helmsley Charitable Trust’s Type 1 Diabetes Program. Prior to T1D First, Imran served as the CBO of MassBio, one of the most influential biotechnology trade associa-tions in the nation. Imran brought a rich synthesis of life science corporate development (emerging and early stage), licensing, and policy. Imran is responsible for building MassBio’s business development and investor outreach programs thereby enabling companies to raise capital and identify strategic partnering and licens-ing opportunities. Imran created MassBio Innovation Services - a suite of services intended to stimulate the creation of new life sciences companies, transfer of life science assets from academia and biotechnology companies to major pharma partners, and solidifying relationships among stakeholders in the life sciences from academia to disease foundations to bio-pharmaceutical companies. Prior to the MBC, Imran worked for Genzyme Corporation, Millennium Pharmaceuticals, Dana Farber Cancer Institute and the Mayo Clinic; all in the business development and licensing capacity. Imran’s experience extends to having negotiated and ex-ecuted complex and varied agreements with biopharmaceutical, academic, and government entities thereby enhancing R&D activities, acquiring strategic assets, accelerating product and service launches. Specialties: Industrial Expertise: business development, collaboration and alliance formation, and intellectual property licensing. Responsible for evaluating, negotiating, and licensing technology and oncology therapeutics and diagnostics. Imran has an M.S. from the University of Colorado, Boulder, in exercise biochemistry, and his Juris Doctor, from Suffolk University Law School in Boston, MA.

Bernat OllePrincipal, PureTech Ventures

Dr. Olle is a Principal at PureTech Ventures. He has been a member of the founding teams of Follica, Inc, Vedanta Biosciences, and Enlight Biosciences. He serves as the Chief Operating Officer and a member of the Board of Directors of Vedanta Biosciences. He completed his doctoral work at the Chemical Engineering Department at MIT, where he co-developed a novel method to increase oxygen transfer in bioreactors by using colloidal nanoparticles. During his graduate work, Dr. Olle was awarded the “la Caixa” fellowship by the King of Spain, and also consulted for established chemical and pharmaceutical companies, and life sci-ences start-ups. Dr. Olle received his B.Eng. In Chemical Engineering from Universitat Rovira I Virgili, Spain, his M.S. and PhD in Chemical Engineering Practice from MIT, and his MBA from the MIT Sloan School of Management.


24 Biographies

John ReddingtonCOO, Cambridge Biomedical Inc

Dr. Reddington is the Chief Operating Officer at Cambridge Biomedical Inc., a Clinical Laboratory Research Organization (CLRO) that services the 4 major US reference laboratories with esoteric testing, and the bio-pharmaceutical industries with regulatory-appropriate analytical development, validation and specimen test-ing. Previously, John served as President and CEO of Sirtex Medical, Inc., the US division of an Australian publicly traded company Sirtex Medical Group Ltd. (ASX: SIR), where he reorganized and revitalized the US division which accounted for over 80% of the corporation’s $66 million in revenue.

Prior to joining Sirtex, John was COO and SVP of R&D for the publicly traded company Valentis Inc., where he played a key role in transitioning Valentis’ clinical focus from gene therapy to poloxamer-based thera-peutics to treat cardiovascular disease. During his tenure John helped secure $30 million in new equity financing, as well as negotiated licensing and supply agreements up to $500 million. In addition, he was responsible for selling off all non-critical assets to facilitate a reverse merger, and spun out the manufacturing division as an independent business unit.

Previously, John founded DiagXotics Inc. and led it to become the world leader in disease diagnosis for the $52-billion global aquaculture market. Dr. Reddington received his B.A. from Rice University, his M.A. from the University of Texas, Arlington and his DVM, PhD, and B.S. from Washington State University.

Kiran ReddyPrincipal, Third Rock Ventures

Kiran Reddy is a Principal at Third Rock Ventures and joined the firm in 2008. As a Principal, Kiran supports and manages various portfolio companies in addition to focusing on new company formation and due dili-gence. Presently, he serves as interim Chief Business Officer for SAGE Therapeutics. Kiran was part of the team that launched Foundation Medicine, and he has served as a Board Observer for Alnara pharmaceuti-cals, Rhythm pharmaceuticals, and PanOptica pharmaceuticals. Prior to joining Third Rock Ventures, Kiran was a management consultant at the Lewin Group within in the biotechnology and pharmaceutical practice, and advised clients on clinical development and commercial strategy. Kiran holds MD and MBA degrees from Georgetown University. He completed his internship in medicine and his neurology residency at Harvard / Massachusetts General Hospital and is a board certified neurologist. Kiran was previously a Howard Hughes science fellow, and has authored several peer-reviewed scientific papers in the field of neuroimmunology and neurodegenerative diseases.

William RodriguezCEO, Daktari Diagnostics

William Rodriguez, MD, is a specialist in global health. He trained in internal medicine and infectious dis-eases at the Brigham and Women’s Hospital in Boston, where he served as Chief Medical Resident. From 2003-2007, he was the Chief Medical Officer for the William J. Clinton Foundation, where he assisted the South African government with the development of its national HIV treatment program, and helped broker agreements between more than 60 African and Asian governments and the major suppliers of HIV and TB drugs and diagnostic tests. He has served as a consultant to the World Health Organization and the Bill & Melinda Gates Foundation on HIV and tuberculosis treatment and laboratory systems. From 2001-2008, he co-directed a research program on global health diagnostics at Massachusetts General Hospital. In 2008, he co-founded Daktari Diagnostics, where he serves as the Chief Executive Officer.


Biographies 25

Yael SchwartzCEO & President, Hygeia Therapeutics, Inc

Dr. Yael Schwartz is a life sciences executive with more than 25 years combined drug development and academic experience. She studied Pharmacology and Toxicology at Northeastern University and received her PhD with honors from a joint program between the University of Massachusetts Medical School and WPI in Biomedical Sciences with a specialization in Endocrine Physiology. In 2008, she parlayed her love of endocrine physiology and drug development into founding Hygeia Therapeutics, a company with two lead compounds in woman’s health and dermatology, where she is currently the President and CEO. In 2012, she spun a second company out of Hygeia Therapeutics called Canterbury Laboratories. In conjunction with a major aesthetic dermatology company, Canterbury will launch a commercial product during the winter of 2013 for aging skin. Over the course of her career she exhibited tangible success in helping advance small molecule therapeutics from discovery through NDA submission across multiple therapeutic areas that suc-cessfully led to the development and commercialization of five drugs currently in clinical practice. Periodi-cally, she guest lectures in Pharmacology, Immunology or Physiology at the Massachusetts College of Phar-macy-Worcester where in 2009 she was nominated by her students for induction into Phi Lambda Sigma for exhibiting leadership and dedication in drug discovery and development. For relaxation, Dr. Schwartz hikes, kayaks and participates in pistol marksmanship events.

Mark SullivanFounder and Director, Medicines Development

Mark Sullivan (BSc), Founder and Director of Medicines Development, has 23 years experience in the de-velopment of small molecules, therapeutic and prophylactic vaccines and microbicides. He has worked in clinical research at GlaxoSmithKline in London for 10 years, Gilead Sciences in San Francisco for 2.5 years and the University of New South Wales for 3 years. He has been involved in three development programs that have progressed through successful global registration (3TC for HIV, and lamivudine and adefovir dipiv-oxil programs for chronic hepatitis B) and project led several programs through early stage development to clinical proof of concept. Mark established Medicines Development to manage the development of products targeted for resource poor settings, and funds this through the provision of commercial development in the biotechnology sector.

Ajay VermaVice President, Biogen Idec

Ajay Verma studied zoology at the University of Maryland and received his MD and PhD from The Johns Hopkins University. His neuroscience training was in the laboratory of Dr. Soloman Snyder. His neurology training was at the Walter Reed Army Medical Center where he was a staff Neurologist for 11 years. He was also a tenured Professor in Neurology, Neuroscience, Anesthesiology and Pathology at the Uniformed Service University of the Health Sciences, the US Military’s Medical School. Since leaving the Army as a Lt. Colonel in 2006, he has worked at Merck Inc. and Novartis Pharmaceuticals. He is currently a Vice President at Biogen Idec for Neurodegenerative drug development and Translational Neurology.


26 Biographies

Waynne Waterfield Senior Practice Executive, Campbell Alliance

Waynne is responsible for both business development and engagement management within the Brand and Business Development practices for Campbell Alliance, the leading management consulting firm serving the biopharmaceutical industry. Select services include: market assessments, product forecasting and valuation, indication prioritization and life-cycle planning, portfolio and franchise planning, in-licensing and out-licensing support, TPP development, brand planning, launch planning and launch management.

Previously Waynne served as Vice President and General Manager, Early Stage Commercialization Practice at inVentiv Advance Insights, Group Director at Creative Healthcare Solutions, and Director of Marketing at Healthcare Data Systems. Waynne had over 25 years of commercial experience in the biopharmaceutical industry from discovery to end of life-cycle, including: product strategy, portfolio strategy, brand strategy, part-nering and alliance strategy and brand management. Waynne has shaped product development strategy for numerous compounds in oncology, infectious disease, cardiology and pain. Waynne has led or participated on cross-functional teams to address major development decisions such as target indications, study design and go/no go decisions. Waynne has developed or led teams or worked individually to develop the commer-cial and financial rationale for numerous compounds in development or in support of business development. Waynne graduated from Northeastern University - Graduate School of Business and Administration and University of Michigan - Stephen M. Ross School of Business.

Pamela WeagraffPrincipal Consultant, Quintiles Consulting Medical Device

Ms. Weagraff is a Principal Consultant in the Quintiles Consulting Medical Device Development Practice. Ms. Weagraff delivers strategic and tactical consulting services to ensure appropriate linkages between regula-tory plans, clinical plans, and business strategy; develops and manages regulatory authority communication plans, serves as liaison on behalf of clients; conducts assessments of product and labeling-related compli-ance programs; and assists US and EU clients with commercialization planning. Prior to joining the consul-tancy ranks, Ms. Weagraff had been bringing medical devices through product development to market in a variety of start-up, mid-size and large companies for over 25 years. Ms. Weagraff has been a key contributor to the development and implementation of the company business strategies, including regulatory, clinical and early stage marketing, product management and payment strategies. Ms. Weagraff has extensive interna-tional experience from working and living in the EU. She combines a unique mix of marketing and regulatory expertise in the development and implementation of customer-focused strategies. Known for a collaborative approach with regulatory agencies, Ms. Weagraff integrates regulatory requirements to inform but not drive the business strategy.

Ms. Weagraff has been recognized for her contributions to industry/FDA initiatives at the national and re-gional level and invited to lecture on a variety of FDA issues for industry organizations. In addition to her ap-pointment as HIMA (now AdvaMed) Management Fellow, Ms. Weagraff was also recognized as an AdvaMed Achiever and received Vice President Al Gore’s Hammer Award from the National Partnership for Reinvent-ing Government. Ms. Weagraff was an AdvaMed small company representative in the industry contributions to the drafting of FDAMA and MDUFMA. She currently serves as Regulatory Advisor to the MassMEDIC Board of Directors, and on the boards of MassMEDIC MedTech IGNITE, and Regis College, Health Product Regulations Program. Ms. Weagraff holds a Bachelor of Arts from Pennsylvania State University, Phi Beta Kappa, and a Masters of Business Administration, from Boston University.


Biographies 27

Bruce WentworthSenior Director, Genzyme

Bruce Wentworth is a Senior Director at Genzyme in the Rare Genetic Disease Research Group in Framing-ham, MA. He leads a group of scientists studying the development of potential therapies for genetic muscle diseases such as Myotonic and Duchene’s muscular dystrophies employing diverse technology platforms including small molecules, protein and antibodies, as well as antisense oligonucleotides. Earlier, he was Co-Director of the cardiovascular research portfolio at Genzyme Corporation and Scientific Director of MG Biotherapeutics, a joint venture formed between Medtronic and Genzyme focused on the research and development of cardiovascular cell therapies. Bruce has led various research efforts in during his career at Genzyme and earlier at Biosurface Techology including work developing autologous cultured cell techniques for skin grafting used in burn therapy, the use of cultured chondrocytes for repair of cartilage defects, and the culture of skeletal myoblasts for cardiac repair. He received his BA and MA in biology from Boston University and a PhD from the University of Massachusetts Medical School (‘87) in molecular genetics. Bruce did his postdoctoral training as a Fellow of the American Heart Association studying the mechanisms of gene ex-pression in skeletal muscle at Harvard and Boston University.

James WestonSenior Director CMC, Global Regulatory Affairs, Shire HGT

James Weston joined Shire HGT as the Senior Director CMC, Global Regulatory Affairs in January 2011. Jim is a veteran regulatory executive with a demonstrated ability to spearhead the drug development process by crafting effective regulatory strategies world-wide. His knowledge of domestic and international regula-tory requirements and his close interactions with regulatory authorities has resulted in successful and timely implementation of investigational and marketing applications that resulted in the approval of more than 11 drugs / biologics world-wide. Jim was previously a Senior Regulatory Consultant for BioBridges LLC as well as the Principal Regulatory Consultant for Talaris Advisors LLC. Previous experience included being Senior Vice President of Regulatory Affairs and Quality for Alseres Pharmaceuticals, Vice President Corporate and Regulatory Strategy and Managing Director of Cato Research, senior Regulatory Affairs and Government Relations management positions with Biopure and Regulatory, Clinical Research, Quality Assurance and Quality Control management positions at DuPont Pharmaceuticals. He is a member of and frequent pre-senter for many professional organizations, including the Regulatory Affairs Professionals Society, Drug Information Association, Parenteral Drug Association, and the Special Operations Medical Association and former co-chair of the Quality and Regulatory Committee of the Massachusetts Biotechnology Council.


28 Biographies

Ray WinquistVice President Integrated Biology, Vertex Pharmaceuticals

Dr. Ray Winquist is Vice President, Integrated Biology and Co-Site Head of Research at the Cambridge site for Vertex Pharmaceuticals, Inc. In this capacity, Dr. Winquist heads departments which support research programs in infectious diseases, multiple sclerosis and oncology. Dr. Winquist received his Ph.D. in Phar-macology at the UCLA Medical School and completed a NIH postdoctoral fellowship in the Department of Physiology at the University of Michigan Medical School, focusing mainly on vascular abnormalities in car-diovascular disease. Following his postdoctoral work, Dr. Winquist joined the Pharmacology department at Merke Sharpe and Dohme research labs in West Point, PA, where he worked on lead optimization programs for the indications of hypertension and heart failure. He then joined Boehringer Ingelheim Pharmaceuticals, Inc. in Ridgefield, CT where he became Director of Pharmacology, supporting research programs in autoim-mune, pulmonary and cardiovascular diseases. Dr. Winquist became Vice President of Pharmacology at Scion Pharmaceuticals in Medford, MA in 2003, working in the fields of neuropathic pain and cardiac arrhyth-mias before joining Vertex in 2005.


Planning Committee 29

MALSI Day Planning Committee

Chairs

Abi Barrow, MTTC (Co-Chair)Lauren Laidlaw, MassBio (Co-Chair)

Content

Richard Anders, MA Medical AngelsCarl Berke, Partners Healthcare

Gary Lavine, Waltham ConsultingMark Namchuk, Vertex Pharmaceuticals

Marketplace

Lauren Perna, MassBio

Research & Startup Showcase and Logistics

Julia Goldberg, MTTCShyh-Chang Ng, Harvard Biotech Club

Ting Ren, Campbell Alliance Group

Reception

Lauren Laidlaw, MassBioDenise Aronson, Safety Partners, Inc.

Team

Rakhshita Dhar, MassBioLance Hartford, MassBio Education Foundation

Shyh-Chang Ng, Harvard Biotech Club Kevin O’Sullivan, MA Biotech Incubator

Aaron Sandoski, Norwich Ventures

30 Sponsors & Organizers

5th Annual Massachusetts Life Sciences Innovation Day

Sponsors & Organizers 31


Sponsors and OrganizersGold Sponsors ..................................................................................................................... 34

Massachusetts Life Sciences Center ...........................................................................................................34Pepper Hamilton LLP ...............................................................................................................................35

Conference Supporters ....................................................................................................... 36Lathrop & Gage LLP .................................................................................................................................36MassGlobal Partners ..................................................................................................................................36Vertex Pharmaceuticals .............................................................................................................................36

Organizers ........................................................................................................................... 37Massachusetts Technology Transfer Center ..............................................................................................37MassBio ......................................................................................................................................................38MALSI, MA2 , Harvard Biotechnology Club ...........................................................................................39MALSI .......................................................................................................................................................40

In association with .............................................................................................................. 41Boston Life Science Networking ..............................................................................................................41Harvard Alumni Entrepreneurs .................................................................................................................41Lemelson-MIT ...........................................................................................................................................41M2D2 .........................................................................................................................................................41MASS-AWIS .............................................................................................................................................41Massachusetts Biomedical Initiatives .......................................................................................................41MassChallenge Inc. ....................................................................................................................................41MassMedic .................................................................................................................................................41Massachusetts Technology Collaborative .................................................................................................41Massachusetts Technology Leadership Council ........................................................................................41NCIIA ........................................................................................................................................................41NEVCA .....................................................................................................................................................41North Shore InnoVentures ........................................................................................................................41OPEN.........................................................................................................................................................41The Bioscience Network ...........................................................................................................................41The Capital Network .................................................................................................................................41WEST ........................................................................................................................................................41University of Massachusetts .......................................................................................................................41

BIO 2012 ............................................................................................................................. 42



Gold Sponsor

Creating Jobs

Driving Innovation

Improving Lives www.masslifesciences.com

…Translating good science into good business

www.masslifesciences.com



Gold Sponsor

Ever get the feeling that your lawyers don’t understand what you do? They may know the law, but science or your business? Not so much. You need a law firm steeped in life sciences, who will be your ally at every step from the lab bench to the board room — from the molecule to the market. A law firm with more than half a century of experience in helping scientists and their businesses succeed. You need lawyers who know you and the science — Pepper Hamilton LLP.

Biologically

Berwyn | Boston | Detroit | Harrisburg | Los Angeles | New York | Orange County | Philadelphia | Pittsburgh | Princeton | Washington | Wilmington

www.pepperlaw.com | 617.204.5100

Greg Williams | [email protected] Jeff Libson | [email protected]



Conference Supporters

N A T I O N A L F I R M . M I D W E S T VA L U E .S M

We salute this opportunity for the science and

business communities to connect and collaborate.

The choice of a lawyer is an important decision and should n ot b e b a s e d s o l e ly u p o n adver t isements . For more information, contact Giulio DeConti at (857) 300-4000.



The Massachusetts Technology Transfer Center is funded by the Commonwealth of Massachusetts. Its goal is to support technology transfer activities from public and private research institutions to companies in Mas-sachusetts. To achieve this goal, the Center works with technology transfer offices at Massachusetts research institutions; faculty, researchers, and students who have commercially promising ideas; and companies across the Commonwealth.

_______________________________________________________________________________

The Center: facilitates and accelerates technology transfer between research institutions and Massachusetts • companies;promotes collaboration between research institutions and the Commonwealth’s technology in-• dustry; assists in the growth of Massachusetts companies, including startups, by enhancing technologi-• cal leadership; andsupports regional and statewide economic development priorities. •

_______________________________________________________________________________

The Center supports the commercialization of research technologies through a variety of programs:

The Center provides mentoring to researchers who believe they have a technology that could serve as the basis of a new company. The process includes the development of a business presentation for an expert board of external reviewers.

Commercialization and Entrepreneurial Education seminars and workshops enable researchers to understand the process of commercializing technologies.

Expert technology reviews provide opportunities for Massachusetts research institutes to have external industry experts evaluate technologies and give advice regarding their commercial potential.

Technology Forums allow investors and potential corporate partners to meet with companies formed around technologies developed in Massachusetts research institutes.

www.MaTTCenter.org

www.MassTechPortal.org

[email protected]



The Massachusetts Biotechnology Council is an association of more than 600 biotechnology companies, universities, academic institutions and other organizations dedicated to advancing cutting edge research. We are the leading advocate for the Bay State’s world premier life science cluster. We drive innovation by creating a forum for the biotechnology community to come together. We work to educate policy makers and the general public on the life-changing work biotech companies do every day. Our e� orts help in� uence public policy and advance the economic interests of individual companies as well as the sector as a whole.

Networking and Professional DevelopmentWe bring members together to discuss relevant business and scienti� c issues and share their experiences through members-only committee meetings and networking events. These gatherings allow our members to discuss and share their experiences, ideas and advice about the numerous issues and challenges that life science companies face every day. MassBio, through MassBioEd, also o� ers workforce development courses and training programs for those looking to learn more about speci� c disciplines within the industry.

Access to Capital and Fostering InnovationWith our new Innovation Services arm, MassBio is focused on matching our member companies with the resources they need to move cutting-edge therapies from the bench to the bedside. Programs like our new Pharma Days series and the annual Investors Forum provide a venue for leaders from burgeoning biotech companies to hear about the vision of larger biotech and pharmaceutical companies, venture � rms, and non-dilutive funding sources, and to make connections that may become successful collaborations or strategic partnerships. MassCONNECT links new entrepreneurs with seasoned biotechnology professionals to provide industry expertise, evaluation, and guidance as a means to help commercialize new ideas. The MassBio Innovation Exchange is a web-based search & evaluation portal designed to accelerate commercialization and make industry business development e� orts more e� ective and e� cient.

Purchasing PowerBy aggregating the purchasing power of the members companies within MassBio, the Purchasing Consortium allows members to have a strong presence in the marketplace and bene� t from discounts and top notch customer service. Current Purchasing Consortium contracts allow MassBio members to access savings in key cost centers, including laboratory supplies, o� ce supplies, shipping, waste removal, packaged and bulk gases, instrument maintenance, energy and mobile communications support.

Public Policy and AdvocacyBiotechnology is a complex, highly regulated industry. At MassBio, we work to educate policy makers and the public about the speci� c needs of our companies as they push the boundaries of science to improve our lives. As the state’s leading advocate for our life sciences super cluster, we � ght for public policy initiatives and tax incentives in Massachusetts that will enable biotechnology companies to do their best work. At the same time, we maintain an active presence in Washington to help guide federal legislation.

Economic Development & Industry DataMassBio provides expert advice and guidance to help companies � nd suitable locations and resources as they move to and grow in the Bay State. With initiatives like the BioReady™ Communities Campaign, which rates a municipality’s zoning practices and infrastructure capacity for biotech development, we make Massachusetts a better place for your business. We also collect and disseminate current industry statistics, including employment and VC investment data.

MassBio Signature EventsWe bring together the various components of the life sciences supercluster through several compelling conferences and programs developed around the needs of our members. These events are opportunities for networking, educat-ing and moving the industry forward. Annual events include the Policy Leadership Breakfast, the MassBio Annual Meeting and BioPharm America™.

300 Technology Square, Eighth FloorCambridge, MA 02139

(617) 674-5100www.MassBio.org



We are motivated to leverage what is truly unique about MA

“If I stand in the middle of Mass Ave Bridge, and walk 1 mile in either direction, I have everything I need to start a billion dollar life sciences company”

The Massachusetts Life Sciences Start-up Initiative (MALSI) is a collaborative group of public and private entities that work with emerging biotech and biomed companies. The prime aim of MALSI is to ensure that every life sciences entrepreneur or researcher who has a commercializable idea has easy and rapid access to the vast network of organizations and individuals who can help them realize their dreams. The Massachusetts Technology Transfer Center, Mass MEDIC, TiE Boston, and MassBio have partnered to present the Massachusetts Life Sciences Innovation Day.

In case you have any questions, please contact

Massachusetts Technology Transfer Center at [email protected]

Please join our MALSI Group on LinkedIn.com



The Organizing Committee thanks our Non-Profit Affiliates:



What’s Your

BIO is where you connect with 15,500 business leaders from 65 countries. Find global partners to fund, sustain and advance projects. Stay abreast of the issues shaping the industry. Identify innovations to move your technology forward. It’s all of these objectives and more, all to help you make the most of your BIO.

It’s what you can make happen at BIOTECH’S BIGGEST EVENT.

ReGister today for Full Convention Access & PartnerinG at convention.bio.orG

Follow us:

CONNECT. PARTNER. INNOVATE .

June 18 – 21, 2012 Boston, MA

8493 BIO12_MASTER AD_GENERICBW_LST.indd 1 3/5/12 3:37 PM


Poster Presenters 41

Poster PresentersARKOconsult ...................................................................................................................... 45

Petr Kotal, Managing Director

ASK Diagnostics ................................................................................................................. 45Geoff Schmidt, President

Boston College .................................................................................................................... 45David Kling, Research Assistant Professor ...................................................................................................

Boston University School of Medicine ............................................................................... 45Katrina Steiling, Assistant Professor

Brown University................................................................................................................. 45Yongsong Huang, Professor

Brown University and Rhode Island Hospital .................................................................... 46Yupeng Chen, Post-doctoral fellow

Extend Biosciences, Inc ....................................................................................................... 46Tarik Soliman, Founder and CEO

GVD Corporation ............................................................................................................... 46Erik Handy, Business Development Manager

Massachusetts Institute of Technology ............................................................................... 46Vikramaditya Yadav, Researcher

Microtissues, Inc ................................................................................................................. 46Jeff Morgan, Associate Professor

Plate Technologies ............................................................................................................... 47Sangram Parelkar, Co-founder

Spordiff Therapeutics .......................................................................................................... 47Frederick Jones, CEO

Synubi Pharmaceuticals ...................................................................................................... 47Lambert Edelmann, Founder and CEO

Viridis Bio ........................................................................................................................... 47David Gallo, Sr. Research Associate

VitaThreads .......................................................................................................................... 47Glenn Gaudette, Scientific Founder


42 Poster Presenters

Wellman Center for Photomedicine, MGH ...................................................................... 48Shazia Khan, Postdoctoral Fellow

Worcester Polytechnic Institute .......................................................................................... 48Pam Weathers, Professor

Wyss Institute at Harvard University .................................................................................. 48Mark Cartwright, Staff Scientist

Wyss Institute at Harvard University .................................................................................. 48Geraldine Hamilton, Researcher

Wyss Institute at Harvard University .................................................................................. 48Michael Super, Senior Staff Scientist

Wyss Institute at Harvard University .................................................................................. 49Robert Valentini, Director of Platform Development

Wyss Institute at Harvard University .................................................................................. 49Anna Waterhouse, Postdoctoral Fellow

Wyss Institute at Harvard University .................................................................................. 49David Zhang, Postdoctoral Fellow


43

ARKOconsultPresented by: Petr Kotal, Managing [email protected] Poster Title: Initial Caries Healing/Repair Technology

ASK DiagnosticsPresented by: Geoff Schmidt, [email protected] Poster Title: Novel Cancer Diagnostic

Boston CollegePresented by: David Kling, Research Assistant Professor [email protected] Poster Title: An Ex Vivo Infection Model with Drug Discovery Potential

Boston University School of MedicinePresented by: Katrina Steiling, Assistant [email protected] Poster Title: A Bronchial Airway Gene Expression Signature Of COPD That Is Reflective Of Lung Tissue Disease Processes And Is Reversible With Inhaled Steroids

Brown UniversityPresented by: Yongsong Huang, [email protected] Poster Title: Silver-Thiolate Modified Silica – A Highly Effective New Stationary Phase for the Analysis and Purification of Unsaturated Organic Compounds



Brown University and Rhode Island HospitalPresented by: Yupeng Chen, Post-doctoral [email protected] Poster Title: Novel RNA Drug Delivery Technology via Self-Assembled Nanotubes for Thera-peutic Applications

Extend Biosciences, IncPresented by: Tarik Soliman, Founder and [email protected] Poster Title: A peptide-specific platform technology that improves the half-life and bioavailabil-ity of peptides

GVD CorporationPresented by: Erik Handy, Business Development Manager [email protected] Poster Title: Ultrathin Polymer Coatings for Environmental Protection and Lubrication

Massachusetts Institute of TechnologyPresented by: Vikramaditya Yadav, [email protected] Poster Title: Building Better Drugs

Microtissues, IncPresented by: Jeff Morgan, Associate Professor [email protected] Poster Title: The 3D Petri Dish®: A natural cell culture environment for research, tox testing and drug discovery


45

Plate TechnologiesPresented by: Sangram Parelkar, [email protected] Poster Title: Plate Technologies – Delive ring rapid success and precision in cell based assays

Spordiff TherapeuticsPresented by: Frederick Jones, [email protected] Poster Title: Prevention of C.difficile Colitis by Inhibition of Spore Germination With Chen-odeoxycholate Analogs (Spordiff )

Synubi PharmaceuticalsPresented by: Lambert Edelmann, Founder and [email protected] Poster Title: Treatment for cognitive impairment in Alzheimer’s Disease

Viridis BioPresented by: David Gallo, Sr. Research [email protected] Poster Title: Harnessing the Power of Biliverdin for Organ Transplantation

VitaThreadsPresented by: Glenn Gaudette, Scientific [email protected] Poster Title: Technology for Efficient Delivery of Cell Therapy



Wellman Center for Photomedicine, MGHPresented by: Shazia Khan, Postdoctoral [email protected] Poster Title: Rapid Point-of-Care Fluorescence based Determination of Antibiotic Suscepti-bility

Worcester Polytechnic InstitutePresented by: Pam Weathers, [email protected] Poster Title: From plant to patient: edible delivery of a broad spectrum drug

Wyss Institute at Harvard UniversityPresented by: Mark Cartwright, Staff [email protected] Poster Title: Rapid Detection of Antibiotic Susceptibility From Single Bacterium

Wyss Institute at Harvard UniversityPresented by: Geraldine Hamilton, [email protected] Poster Title: Organ-on-Chip Technologies: Transforming Drug Discovery

Wyss Institute at Harvard UniversityPresented by: Michael Super, Senior Staff [email protected] Poster Title: BioInspired Spleen-on-a-chip Device for Sepsis Therapy


47

Wyss Institute at Harvard UniversityPresented by: Robert Valentini, Director of Platform [email protected] Poster Title: Targeted Nanotherapeutics

Wyss Institute at Harvard UniversityPresented by: Anna Waterhouse, Postdoctoral [email protected] Poster Title: A non-thrombogenic, anti-biofilm surface for medical devices

Wyss Institute at Harvard UniversityPresented by: David Zhang, Postdoctoral [email protected] Poster Title: Highly specific hybridization probes


Innovator's Marketplace Exhibitors 49

Innovators’ Marketplace Exhibitors


50 Innovator's Marketplace Exhibitors

Life Science Products and Services

ALPCO Diagnostics .......................................................................................... www.alpco.com

Biologics Consulting Group, Inc. ................................................................... www.bcg-usa.com

Complya Consulting Group, LLC ...................................................................www.complya.com

Covaris Inc. ................................................................................................www.covarisinc.com

MedChem Partners .......................................................................www.medchempartners.com

Toxikon Corp ....................................................................................................www.toxikon.com

Sunrise Labs, Inc. .....................................................................................www.sunriselabs.com

Vertex ................................................................................................................... www.vrtx.com

Entrepreneurship Support

Massachusetts Life Sciences Center ..............................................www.masslifesciences.com

Massachusetts Technology Trasfer Center .................................................www.mattcenter.org

MassBio .......................................................................................................... www.massbio.org

MALSI ............................................................................ www.linkedin.com/groups?gid=113959

Harvard Biotechnology Club ................................................................. www.thebiotechclub.org

Boston Life Science Networking ..................................................... www.bostonlifescience.com

Harvard Alumni Entrepreneurs ....................................... www.harvardalumnientrepreneurs.org

Lemelson-MIT Program ................................................................................ web.mit.edu/invent

MASS-AWIS ................................................................................................www.mass-awis.org

Massachusetts Biomedical Initiatives ...................................................... www.massbiomed.org

Massachusetts Medical Device Development Center (M2D2) ...................www.uml.edu/m2d2

MassMedic ...............................................................................................www.massmedic.com

Massachusetts Technology Leadership Council ............................... www.masstechleaders.org

Massachusetts Technology Collaborative .................................................... www.masstech.org

MassGlobal Partners ...................................................................www.massglobalpartners.com

MVVF ....................................................................................................................www.mvvf.org

NCIIA .................................................................................................................... www.nciia.org

North Shore InnoVentures ..................................................................................... www.nsiv.org


Innovator's Marketplace Exhibitors 51

OPEN ............................................................................................ www.open-newengland.com

TiE ................................................................................................................www.tie-boston.org

The Bioscience Network ............................................................www.thebiosciencenetwork.org

WEST ..............................................................................................................www.westorg.org

Funding

CIMIT .................................................................................................................... www.cimit.org

Mass Medical Angels ........................................................................www.massmedangels.com

MassChallenge Inc. ..............................................................................www.masschallenge.org

New England Venture Capital Association ............................................www.newenglandvc.org

The Capital Network – TCN ..............................................................www.thecapitalnetwork.org

Professional Services

Lathrop & Gage LLP ................................................................................www.lathropgage.com

Pepper Hamilton LLP .................................................................................www.pepperlaw.com


52 Innovator's Marketplace Exhibitors

Notes

may 30, 2012 welcome to the fifth massachusetts life...

Documents